SAN DIEGO, Dec. 8, 2014 /PRNewswire/ -- Organovo Holdings,
Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology
company focused on delivering breakthrough 3D bioprinting
technology, announced today Kirk D. Malloy, Ph.D. has been
appointed to the Company's Board of Directors. Dr. Malloy has held
management and executive leadership positions in rapidly growing
life science and diagnostics companies for 18 years. He is
currently Senior Vice President and General Manager of Life
Sciences at Illumina, a leading developer and supplier of genetic
analysis instrumentation, assays and software for the life science
and diagnostics markets.
"Organovo's 3D bioprinting technology has broad applications in
disease research and drug discovery. We welcome Dr. Malloy's
experience in advancing industry-changing technology platforms and
building commercial growth in the life science markets," said
Organovo Chief Executive Officer Keith
Murphy.
"Organovo has a strong foundation with their unmatched
commercial 3D bioprinting technology and numerous industry and
research collaborations. I look forward to helping the team further
their collaborations and develop new opportunities for the life
science markets as Organovo proceeds to create a range of tissue
and disease models for medical research, drug testing and
therapeutic applications," said Dr. Malloy.
At Illumina, Dr. Malloy oversees the company's core platform
technologies and the core life sciences markets they enable. He
joined Illumina in 2002 and has served as Vice President of
Customer Solutions and Vice President of Quality, building and
leading the commercial support organization and a robust service
business for all of Illumina's markets. Prior to joining Illumina,
Dr. Malloy built and managed training, support and validation
services at Biosite Inc., a leading provider of rapid diagnostics
products, where he helped build the point of care cardiovascular
diagnostics test market. Before Biosite, Dr. Malloy held several
commercial management positions at QIAGEN, Inc., a provider of
molecular biology reagents and for the life sciences, veterinary,
diagnostics, and applied markets. Before joining industry, Dr.
Malloy spent several years as an academic scientist teaching and
conducting research.
Dr. Malloy earned his B.S. in biology from the University of Miami and his M.S. and Ph.D. from the
University of Delaware and held
post-doctoral positions at Boston
University and Northeastern
University. He completed a certification for Corporate
Directors at UCLA Anderson School of Management.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for use in medical research and therapeutic applications.
The Company develops 3D human disease models through internal
development and in collaboration with pharmaceutical and academic
partners. Organovo's 3D human tissues have the potential to
accelerate the drug discovery process, enabling treatments to be
developed faster and at lower cost. The company recently launched
its initial product of the planned exVive3DTM portfolio offering, a
3D Human Liver Tissue for use in Toxicology and other preclinical
drug testing. Additional products, including a 3D Kidney Model, are
in development with anticipated release for use in the latter half
of calendar year 2016. The company also actively conducts
early research on specific tissues for therapeutic use in direct
surgical applications. In addition to numerous scientific
publications, the Company's technology has been featured in The
Wall Street Journal, Time Magazine, The Economist, and numerous
others. Organovo is changing the shape of medical research and
practice. Learn more at www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
Company's ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the market acceptance of the Company's
products; and the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in our filings with the SEC, including our
annual report on Form 10-K filed with the SEC on June 10, 2014 and its report on Form 10-Q filed
with the SEC on November 7, 2014, as
well as our other filings with the SEC. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the
United States, we do not intend to update any of the
forward-looking statements to conform these statements to reflect
actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/organovo-appoints-dr-kirk-malloy-to-board-of-directors-300005708.html
SOURCE Organovo Holdings, Inc.
